undamentalytics Newsletter
Sign in

Definium Therapeutics, Inc. (DFTX) stock

Add to watchlist

Add holding +

NASDAQ: DFTX Nasdaq Pharmaceuticals Next results ~November 9, 2026

Definium Therapeutics, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 17 sales by directors and officers, last 12 monthsInsider trades
  • Funds256 adding, 93 cuttingOf 62 active managers that changed their stake, 43 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 162% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Definium Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 78% and a beta of 1.1 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results

Earnings per share
-$1.44 against an average estimate of -$0.55: missed by 162.2%
Share reaction
+3.9% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$0.56

Definium Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-10.6%
  • 1 week-9.0%
  • 1 month-13.2%
  • This year+142.5%
  • 1 year+128.7%
  • 5 years-21.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Announcement
  3. Announcement
  4. Announcement
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Definium Therapeutics, Inc. valuation models and calculator

No model value for Definium Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.56 (range −$0.70 to −$0.45) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.19 −55% — 0%
Next −$1.94 +39% $29m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +44.2% on 90 days ago. In the last 30 days, 2 analysts raised Definium Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Definium Therapeutics, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.21 Current fiscal year, 60 days ago: −$3.16 Current fiscal year, 30 days ago: −$3.16 Current fiscal year, 7 days ago: −$3.18 Current fiscal year, Now: −$3.19 −$3.19 Next fiscal year, 90 days ago: −$1.48 Next fiscal year, 60 days ago: −$1.88 Next fiscal year, 30 days ago: −$1.90 Next fiscal year, 7 days ago: −$1.94 Next fiscal year, Now: −$1.94 −$1.94

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.21−$1.48
60 days ago −$3.16−$1.88
30 days ago −$3.16−$1.90
7 days ago −$3.18−$1.94
Now −$3.19−$1.94

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.55 −$1.44 −162.2%
Mar 2026 −$0.49 −$0.71 −44.0%
Dec 2025 −$0.49 −$0.50 −2.0%
Sept 2025 −$0.50 −$0.78 −54.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

19 analysts, Oct 2026
Buy19100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202651419
  2. Sep 202641418
  3. Aug 202641418
  4. Jul 202641317

Counts of recommendations published by analysts covering Definium Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.5%
of tradable shares
Days to cover
4.32
at average volume
Short interest, 1 month
−15%
to October 15, 2026
Held by institutions
96%
of shares
Held by insiders
2.6%
of shares
Employees
105
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
DFTX−55%−89%+66%+90%+92%+143%
Industry peers (median)−18%−49%−14%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
DFTX33%33%58%58%50%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
DFTX−71%−91%−51%−56%−51%−34%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 15, 2016: 100% from March 17, 2017 to December 17, 2019. Getting back needed a 124900% gain, reached on November 20, 2020, 339 days after the low.

Price behaviour

52-week range
$10.68 – $48.45
From 52-week high
−33.0%
vs 50-day average
−13.5%
vs 200-day average
+9.4%
Volatility (1 year)
78%
Beta vs S&P 500
1.06

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±6.4%
After a week
4 up, 8 down
typical move ±8.1%
After a month
5 up, 7 down
typical move ±10.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +3.9% +0.5% −1.1% −14.2%
May 7, 2026 −5.8% +0.5% −8.8% −1.7%
February 26, 2026 −1.0% −1.0% −0.4% +1.5%
January 12, 2026 +7.4% 0.0% +21.2% +25.4%
November 6, 2025 +1.5% −1.0% +0.9% +12.7%
October 29, 2025 +4.0% −1.1% −10.4% −1.7%
July 31, 2025 −6.5% −2.0% +10.6% −1.7%
May 8, 2025 −6.7% +0.6% −0.6% +17.8%
March 6, 2025 +7.1% −1.2% −1.1% −14.9%
November 7, 2024 +25.8% +1.2% +24.3% +7.9%
August 13, 2024 −2.8% +2.0% −9.9% −9.8%
August 12, 2024 −4.6% +1.7% −8.0% −13.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$5.3B
Institutions reporting
357
Shares held vs prior quarter
▲ 46.5%
Positions opened / closed
141 / 29

Top buyers and sellers, Q2 2026: 256 institutions bought and 93 sold ; the biggest buyer was Capital World Investors (+5.4M shares) and the biggest seller Trails Edge Capital Partners, LP (−1.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $528M 11.2M 9.9% ▲ 32.5%
Avoro Capital Advisors LLC $338M 7.2M 6.3% ▲ 43.8%
Driehaus Capital Management LLC $322M 6.8M 6.0% ▲ 15.8%
Jupiter Topco LLC $264M 5.6M 4.9% —
Capital World Investors $252M 5.4M 4.7% New
FMR LLC $224M 4.8M 4.2% ▲ 162.6%
Price T Rowe Associates Inc $219M 4.7M 4.1% ▲ 6545.7%
Geode Capital Management, LLC $171M 3.6M 3.2% ▲ 46.1%
State Street Corp $144M 3.1M 2.7% ▲ 24.0%
Capital International Investors $139M 3.0M 2.6% New
Octagon Capital Advisors LP $139M 3.0M 2.6% ▲ 20.9%
Wellington Management Group LLP $139M 2.9M 2.6% ▲ 126.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Definium Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $7M 17 trades by 5 insiders · 100% under pre-set plans
Net ▼ $7M net selling
Insider Date Trade Shares Price Value
Roberts Brandi Chief Financial Officer September 25, 2026 Sell pre-set plan 3,377 $36.57 $123,497
Sullivan Mark Chief Legal Officer September 25, 2026 Sell pre-set plan 14,051 $36.57 $513,845
Wiley Matthew T. Chief Commercial Officer September 25, 2026 Sell pre-set plan 3,097 $36.57 $113,257
Barrow Robert Chief Executive Officer September 25, 2026 Sell pre-set plan 31,550 $36.57 $1.2M
Karlin Daniel Chief Medical Officer September 25, 2026 Sell pre-set plan 10,853 $36.57 $396,894
Barrow Robert Chief Executive Officer September 3, 2026 Sell pre-set plan 19,023 $37.94 $721,733
Wiley Matthew T. Chief Commercial Officer June 25, 2026 Sell pre-set plan 2,867 $45.03 $129,101
Barrow Robert Chief Executive Officer June 25, 2026 Sell pre-set plan 29,208 $45.03 $1.3M
Roberts Brandi Chief Financial Officer June 25, 2026 Sell pre-set plan 3,013 $45.03 $135,675
Karlin Daniel Chief Medical Officer June 25, 2026 Sell pre-set plan 10,035 $45.03 $451,876
Sullivan Mark Chief Legal Officer June 25, 2026 Sell pre-set plan 13,008 $45.03 $585,750
Barrow Robert Chief Executive Officer March 25, 2026 Sell pre-set plan 24,431 $18.47 $451,241

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 6, 2026
  • May 7, 2026
  • February 26, 2026
  • January 12, 2026
  • November 6, 2025
  • October 29, 2025

Recent SEC filings

Data status

When each part of this page on Definium Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Definium Therapeutics, Inc. in brief

What does Definium Therapeutics, Inc. do?
Definium Therapeutics, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Definium Therapeutics, Inc.'s stock ticker?
Definium Therapeutics, Inc. trades under the ticker DFTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Definium Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Avoro Capital Advisors LLC and Driehaus Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Definium Therapeutics, Inc. stock?
Over the last 12 months, Definium Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 17 sales on Form 4. The insider trading page charts every trade.
When is Definium Therapeutics, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Definium Therapeutics, Inc. announces its own schedule.